Эндотелиальная дисфункция – фармакологическая мишень в терапии аффективных расстройств у пациентов с сердечно-сосудистыми заболеваниями

1. Dahlof B. Cardiovascular disease risk factors: epidemiology and risk assessment. Am J Cardiol 2010; 105 (Suppl. 1): 3A–9A.
2. Lloyd-Jones DM, Hong Y, Labarthe D et al. Defining and setting national goals for cardiovascular health promotion and disease reduction. Circulation 2010; 121 (4): 586–613.
3. Waldman SA, Terzic A. Cardiovascular health: the global challenge. Clin Pharmacol Ther 2011; 90 (4): 483–5.
4. Lepin JP, Briley M. The increasing burden of depression. Neuropsychiatr Dis Treat 2011; 7 (Suppl. 1): 3–7.
5. Brodtmann A. Vascular risk, depression, and stroke: post hoc ergopropter hoc … or not. Neurology 2014; 83: 1688–9. DOI: 10.1212/WNL.0000000000000968
6. Kubzansky LD, Winning A, Kawachi I. Affective states and health. In: Berkman LF, Kawachi I, Glymour MM, eds. Social Epidemiology. New York: Oxford University Press, 2014; p. 320–64.
7. Gilsanz P, Kubzansky LD, Tchetgen Tchetgen EJ et al. Changes in Depressive Symptoms and Subsequent Risk of Stroke in the Cardiovascular Health Study. Stroke 2017; 48–50. DOI: 10.1161/STROKEAHA.116.013554
8. Pan A, Sun Q, Okereke OI et al. Depression and risk of stroke morbidity and mortality: a meta-analysis and systematic review. JAMA 2011; 306: 1241–9. DOI: 10.1001/jama.2011.1282
9. Dong JY, Zhang YH, Tong J, Qin LQ. Depression and risk of stroke: a meta-analysis of prospective studies. Stroke 2012; 43: 32–7. DOI: 10.1161/STROKEAHA.111.630871
10.  Wulsin L, Singal B. Do depressive symptoms increase the risk for the onset of coronary disease? A systematic quantitative review. Psychosom Med 2003; 65: 201–10.
11. Robins JM, Hernán MA, Brumback B. Marginal structural models and causal inference in epidemiology. Epidemiology 2000; 11: 550–60.
12. Gilsanz P, Walter S, Tchetgen Tchetgen EJ et al. Changes in depressive symptoms and incidence of first stroke among middle-aged and older US adults. J Am Heart Assoc 2015; 4: 19–23.
13. Dantzer R, O’Connor JC, Freund GG et al. From inflammation to sickness and depression: when the immune system subjugates the brain. Nat Rev Neurosci 2008; 9 (1): 46–56.
14. Dinan TG. Inflammatory markers in depression. Curr Opin Psychiatry 2008; 22: 32–6.
15. Haroon E, Raison CL, Miller AH. Psychoneuroimmunology Meets neuropsychopharmacology: translational implications of the impact of inflammation on behavior. Neuropsychopharmacol Rev 2012; 37: 137–62.
16. Leonard BE. The concept of depression as a dysfunction of the immune system. Curr Immunol Rev 2010; 6 (3): 205–12.
17. Irwin MR, Cole JC. Depression and psychoneuroimmunology. Human Psychoneuroimmunology [Internet]. Oxford University Press, 2005; p. 243–64.
18. Prather AA, Vogelzangs N, Penninx BWJH. Sleep duration, insomnia, and markers of systemic inflammation: Results from the Netherlands Study of Depression and Anxiety (NESDA). J Psychiatr Res 2015; 60: 95–102.
19. Motivala SJ, Sarfatti A, Olmos L, Irwin MR. Inflammatory Markers and Sleep Disturbance in Major Depression. Psychosomatic Medicine. Ovid Technologies (Wolters Kluwer Health) 2005; 67 (2): 187–94. DOI: 10.1097/01.psy.0000149259.72488.09
20. Cho HJ, Seeman TE, Kiefe CI et al. Sleep disturbance and longitudinal risk of inflammation: Moderating influences of social integration and social isolation in the Coronary Artery Risk Development in Young Adults (CARDIA) study. Brain Behav Immun 2015; 1–8. DOI: 10.1016/j.bbi.2015.02.023
21. Michetti F, Massaro A, Murazio M. The nervous system-specific S-100 antigen in cerebrospinal fluid of multiple sclerosis patients. Neuroscience Letters 1979; 11 (2): 171–5.
22. Pizzi C, Costa GM, Santarella L et al. Depression symptoms and the progression of carotid intima-media thickness: a 5-year follow-up study. Atherosclerosis 2014; 233: 530–6. DOI: 10.1016/j.atherosclerosis.2014.01.012
23. Herrmann LL, Le Masurier M, Ebmeier KP. White matter hyperintensities in late life depression: a systematic review. J Neurol Neurosurg Psychiatry 2008; 79: 619–24. DOI: 10.1136/jnnp.2007.124651
24. Aydin Sunbul E, Sunbul M, Gulec H. The impact of major depression on heart rate variability and endothelial dysfunction in patients with stable coronary artery disease. Gen Hosp Psychiatry 2017; 44: 4–9. DOI: 10.1016/j.genhosppsych
25. Tilton RG, Chang KC, LeJeune WS et al. Role for nitric oxide in the hyperpermeability and hemodynamic changes induced by intravenous VEGF. Investig Ophthalmol Vis Sci 1999; 40: 689–96.
26. Taddei S, Virdis A, Mattei P et al. Endothelium-dependent forearm vasodilation is reduced in normotensive subjects with familial history of hypertension. J Cardiovasc Pharmacol 1992; 20 (Suppl. 12): S193–S195.
27. Landmesser U, Drexler H. Endothelial function and hypertension. Curr Opin Cardiol 2007; 22 (4): 316–20.
28. Bonetti PO, Lerman LO, Lerman A. Endothelial dysfunction: a marker of atherosclerotic risk. Arterioscler Thromb Vasc Biol 2003; 23 (2): 168–75.
29. Kim JS. Cytokines and adhesion molecules in stroke and related diseases. J Neurol Sci 1996; 137: 69–78.
30. Connor TJ, Leonard BE. Depression, stress and immunological activation: the role of cytokines in depressive disorders. Life Sci 1998; 62: 583–606.
31. Thomas AJ, Ferrier IN, Kalaria RN et al. Elevation in late-life depression of intercellular adhesion molecule-1 expression in the dorsolateral prefrontal cortex. Am J Psychiatry 2000; 157: 1682–4.
32. Thomas AJ, Ferrier IN, Kalaria RN et al. Cell adhesion molecule expression in the dorsolateral prefrontal cortex and anterior cingulate cortex in major depression in the elderly. Br J Psychiatry 2002;181: 129–34.
33. Небиеридзе Д.В., Рогов В.А., Оганов Р.Г. Агонисты имидазолиновых рецепторов: новое поколение препаратов центрального действия с новыми возможностями контроля артериальной гипертонии. Рос. кардиол. журн. 2001; 6: 68–73. / Nebieridze D.V., Rogov V.A., Oganov R.G. Agonisty imidazolinovykh retseptorov: novoe pokolenie preparatov tsentral'nogo deistviia s novymi vozmozhnostiami kontrolia arterial'noi gipertonii. Ros. kardiol. zhurn. 2001; 6: 68–73. [in Russian]
34. Ota H, Eto M, Kano MR et al. Induction of endothelial nitric oxide synthase, sirt1, and catalase by statins inhibits endothelial senescence through the akt pathway. Arterioscler Thromb Vasc Biol 2010; 30: 2205–11.
35. Nemeroff CB, Musselman DL. Are platelets the link between depression and ischemic heart disease? Am Heart J 2000; 140 (Suppl. 4): 57–62.
36. Piletz JE, Halaris A, Iqbal O et al. Pro-inflammatory biomarkers in depression: treatment with venlafaxine. World J Biol Psychiatry 2009; 10: 313–23.
37. Piletz JE, Zhu H, Madakasira S et al. Elevated P-selectin on platelets in depression: response to bupropion. J Psychiatry Res 2000; 34: 397–404.
38. Charney DS, Menkes DB, Heninger GR. Receptor sensitivity and the mechanism of action of antidepressant treatment. Implications for the etiology and therapy of depression. Arch Gen Psychiatry 1981; 38: 1160–80.
39. Cook EH, Fletcher KE, Wainwright M et al. Primary structure of the human platelet serotonin 5-HT2A receptor: identify with frontal cortex serotonin 5-HT2A receptor. J Neurochem 1994; 63: 465–9.
40. Marcusson JO, Ross SB. Binding of some antidepressants to the 5-hydroxytryptamine transporter in brain and platelets. Psychopharmacology 1990; 102: 145.
41. De Clerck F. Effects of serotonin on platelets and blood vessels. J Cardiovasc Pharmacol 1991; 17 (Suppl. 5): S1–S5.
42. Nemeroff C, Musselman D. Are platelets the link between depression and ischemic heart disease? Am Heart J 2000; 140: 57–62.
43. Pollock BGM, Laghrissi-Thode FM, Wagner WRP. Evaluation of platelet activation in depressed patients with ischemic heart disease after paroxetine or nortriptyline treatment. J Clin Psychopharmacol 2000; 20: 137–40.
44. Nakashima MN, Ajiki K, Nakashima K, Takahashi M. Possible role of nitric oxide in anxiety following transient cerebral ischemia in mice. J Pharmacol Sci 2003; 91: 47–52.
45. Bonetti PO, Lerman LO, Lerman A. Endothelial dysfunction: a marker of atherosclerotic risk. Arterioscler Thromb Vasc Biol 2003; 23: 168–75.
46. Cleland SJ, Sattar N, Petrie JR et al. Endothelial dysfunction as a possible link between C-reactive protein levels and cardiovascular disease. Clin Sci 2000; 98: 531–5.
47. Markovitz JH, Shuster JL, Chitwood WS et al. Platelet activation in depression and effects of sertraline treatment: An open-label study. Am J Psychiatry 2000;157: 1006–8.
48. Ziegelstein RC, Parakh K, Sakhuja A, Bhat U. Depression and coronary artery disease: is there a platelet link? Mayo Clin Proc 2007; 82: 1366–8.
49. Tiemeier H. Vitamin B12, folate and homocysteine in depression. The Rotterdam Study. Am J Psychiatry 2002; 159: 2099–101.
50. Zhou L, Zhu DY. Neuronal nitric oxide synhase: structure, subcellular localization, regulation, and clinical implications. Nitric Oxide 2009; 20: 223–30.
51. Joca SR, Guimaraes FS. Inhibition of neuronal nitric oxide synthase in the rat hippocampus induces antidepressant-like effects. Psychopharmacology 2006; 185: 298–305.
52. Herken H, Uz E, Ozyurt H et al. Red blood cell nitric oxide levels in patient with schizophrenia. Schizophr Res 2001; 52: 289–90.
53. Miguel TT, Nunes-de-Souza RL. Anxiogenic like effects induced by NMDA receptor activation are prevented by inhibition or neuronal nitric oxide synthase in the periaqueductal gray in mice. Brain Res 2008; 13: 39–46.
54. Workman JL, Trainor BC, Finy MS et al. Inhibition of neuronal nitric oxide reduces anxiety-like responses to pair housing. Behav Brain Res 2008; 187: 109–15.
55. Яковлев В.М., Семенкин А.А., Юдин С.М. и др. Влияние терапии эналаприла малеатом на функцию сосудистого эндотелия и тромбоцитарно-эндотелиальные взаимосвязи у больных гипертонической болезнью. Терапевт. арх. 2000; 1: 12–5. / Iakovlev V.M., Semenkin A.A., Iudin S.M. i dr. Vliianie terapii enalaprila maleatom na funktsiiu sosudistogo endoteliia i trombotsitarno-endotelial'nye vzaimosviazi u bol'nykh gipertonicheskoi bolezn'iu. Terapevt. arkh. 2000; 1: 12–5. [in Russian]
56. Ситникова М.Ю., Иванов С.Г., Хмельницкая К.А. Фармакологическая защита эндотелия в рамках стандартной терапии хронической сердечной недостаточности. Бюл. НИИ кардиологии им. В.А.Алмазова. 2004; 2 (1): 101–8. / Sitnikova M.Iu., Ivanov S.G., Khmel'nitskaia K.A. Farmakologicheskaia zashchita endoteliia v ramkakh standartnoi terapii khronicheskoi serdechnoi nedostatochnosti. Biul. NII kardiologii im. V.A.Almazova. 2004; 2 (1): 101–8. [in Russian]
57. Luscher TF, Noll G. The endothelium as a regulator of vascular tone and growth. The endothelium in cardiovascular disease: pathophysiology, clinical presentation, and pharmacotherapy. Berlin, 1995; p. 1–24. DOI: 10.1007/978-3-642-79803-0_1
58. Артюшкова Е.Б. Фармакологическая коррекция эндотелиальной дисфункции на ADMA-подобной модели дефицита оксида азота препаратами с различными механизмами действия как дополнение к существующим методам профилактики и лечения сердечнососудистого континуума: информационное письмо. Курск, 2009. / Artiushkova E.B. Farmakologicheskaia korrektsiia endotelial'noi disfunktsii na ADMA-podobnoi modeli defitsita oksida azota preparatami s razlichnymi mekhanizmami deistviia kak dopolnenie k sushchestvuiushchim metodam profilaktiki i lecheniia serdechnososudistogo kontinuuma: informatsionnoe pis'mo. Kursk, 2009. [in Russian]
59. Трухан Д.И. Коррекция нарушений липидного обмена у пациентов с метаболическим синдромом: фокус на розувастатин. Справочник поликлинического врача. 2015; 11–12: 4–8. / Trukhan D.I. Korrektsiia narushenii lipidnogo obmena u patsientov s metabolicheskim sindromom: fokus na rozuvastatin. Handbook for Practitioners Doctors. 2015; 11–12: 4–8. [in Russian]
60. Гончарова Н.С., Моисеева О.М. Простаноиды при легочной венозной гипертензии: зачем, кому, когда и как? РМЖ. 2015; 5: 284. / Goncharova N.S., Moiseeva O.M. Prostanoidy pri legochnoi venoznoi gipertenzii: zachem, komu, kogda i kak? RMZh. 2015; 5: 284. [in Russian]
61. Шилов А.М. Ацетилсалициловая кислота – антиагрегант для профилактики и лечения сердечно-сосудистых заболеваний. Трудный пациент. 2013; 4: 3–8. / Shilov A.M. Atsetilsalitsilovaia kislota – antiagregant dlia profilaktiki i lecheniia serdechno-sosudistykh zabolevanii. Trudnyi patsient. 2013; 4: 3–8. [in Russian]
62. Петрова М.М., Салмина А.Б., Инжутова А.И., Бахметьева О.С. Ингибиторы АПФ – рациональная фармакотерапия эндотелиальной дисфункции. Рациональная фармакотерапия в кардиологии. 2008; 2: 30–4. / Petrova M.M., Salmina A.B., Inzhutova A.I., Bakhmet'eva O.S. Ingibitory APF – ratsional'naia farmakoterapiia endotelial'noi disfunktsii. Ratsional'naia farmakoterapiia v kardiologii. 2008; 2: 30–4. [in Russian]
63. Бритов А.Н. Эндотелиальная дисфункция и роль нитратов и бета-адреноблокаторов в ее коррекции при ишемической болезни сердца. Рациональная фармакотерапия в кардиологии. 2016; 2: 43–7. / Britov A.N. Endotelial'naia disfunktsiia i rol' nitratov i beta-adrenoblokatorov v ee korrektsii pri ishemicheskoi bolezni serdtsa. Ratsional'naia farmakoterapiia v kardiologii. 2016; 2: 43–7. [in Russian]
64. Белоус А.С., Покровская Т.Г., Покровский М.В. и др. Изучение эндотелиопротективных эффектов импазы в комплексе с лозартаном при экспериментальном моделировании L-NAME индуцированного дефицита оксида азота. В кн.: XV Российский национальный конгресс «Человек и лекарство». М., 2008; с. 589. / Belous A.S., Pokrovskaia T.G., Pokrovskii M.V. i dr. Izuchenie endotelioprotektivnykh effektov impazy v komplekse s lozartanom pri eksperimental'nom modelirovanii L-NAME indutsirovannogo defitsita oksida azota. V kn.: XV Rossiiskii natsional'nyi kongress “Chelovek i lekarstvo”. M., 2008; s. 589. [in Russian]
65. Белоус А.С., Покровский М.В., Покровская Т.Г. и др. Эндотелиопротективные эффекты препарата импаза на 30-дневной модели L-NAME индуцированного дефицита оксида азота. В кн.: XVII Российский национальный конгресс «Человек и лекарство». М., 2010; с. 579. / Belous A.S., Pokrovskii M.V., Pokrovskaia T.G. i dr. Endotelioprotektivnye effekty preparata impaza na 30-dnevnoi modeli L-NAME indutsirovannogo defitsita oksida azota. V kn.: XVII Rossiiskii natsional'nyi kongress “Chelovek i lekarstvo”. M., 2010; s. 579. [in Russian]
66. Панкова Т.М., Старостина М.В., Штарк М.Б., Эпштейн О.И. Нейропротекторное действие сверхмалых доз антител к белку S100 в культуре нейробластомы при депривации кислорода и глюкозы. Бюл. экспериментальной биологии и медицины. 2007; 144 (9): 260–3. / Pankova T.M., Starostina M.V., Shtark M.B., Epshtein O.I. Neiroprotektornoe deistvie sverkhmalykh doz antitel k belku S100 v kul'ture neiroblastomy pri deprivatsii kisloroda i gliukozy. Biul. eksperimental'noi biologii i meditsiny. 2007; 144 (9): 260–3. [in Russian]
67. Арустамова А.А. Противоишемическое и эндотелиопротективное действие потенцированных антител к эндотелиальному фактору роста сосудов. Автореф. дис. ... канд. биол. наук. Белгород, 2011. / Arustamova A.A. Protivoishemicheskoe i endotelioprotektivnoe deistvie potentsirovannykh antitel k endotelial'nomu faktoru rosta sosudov. Avtoref. dis. ... kand. biol. nauk. Belgorod, 2011. [in Russian]
68. Белоус А.С. Оценка коррекции морфологических изменений при моделировании эндотелиальной дисфункции сверхмалыми дозами антител к ENOS на 28-дневной модели L-NAME индуцированного дефицита оксида азота. Науч. ведомости. 2014; 11 (182. Вып. 26/1): 127–30. / Belous A.S. Otsenka korrektsii morfologicheskikh izmenenii pri modelirovanii endotelial'noi disfunktsii sverkhmalymi dozami antitel k ENOS na 28-dnevnoi modeli L-NAME indutsirovannogo defitsita oksida azota. Nauch. vedomosti. 2014; 11 (182. Vyp. 26/1): 127–30. [in Russian]
69. Хакимова Г.Р., Воронина Т.А., Дугина Ю.Л. и др. Спектр фармакологических эффектов антител к белку S-100 в релиз-активной форме и механизмы их реализации. Журн. неврологии и психиатрии им. С.С.Корсакова. 2016; 4: 100–13. / Khakimova G.R., Voronina T.A., Dugina Iu.L. i dr. Spektr farmakologicheskikh effektov antitel k belku S-100 v reliz-aktivnoi forme i mekhanizmy ikh realizatsii. Zhurn. nevrologii i psikhiatrii im. S.S.Korsakova. 2016; 4: 100–13. [in Russian]
70. Чуканова Е.И., Боголепова А.Н., Чуканова А.С. Опыт применения препарата диваза в терапии цереброваскулярной недостаточности. Журн. неврологии и психиатрии им. С.С.Корсакова. 2015; 6: 110–4. / Chukanova E.I., Bogolepova A.N., Chukanova A.S. Opyt primeneniia preparata divaza v terapii tserebrovaskuliarnoi nedostatochnosti. Zhurn. nevrologii i psikhiatrii im. S.S.Korsakova. 2015; 6: 110–4. [in Russian]
71. Фатеева В.В., Колоколов О.В., Захарова Н.Б. и др. Хроническая ишемия головного мозга. Лечащий врач. 2016; 5: 1–6. / Fateeva V.V., Kolokolov O.V., Zakharova N.B. i dr. Khronicheskaia ishemiia golovnogo mozga. Lechashchii vrach. 2016; 5: 1–6. [in Russian]
72. Фатеева В.В., Шумахер Г.И., Воробьева Е.Н. и др. Клинико-лабораторное исследование эффективности и безопасности применения препарата Диваза в терапии пациентов с хронической ишемией головного мозга. Журн. неврологии и психиатрии им. С.С.Корсакова. 2017; 2. / Fateeva V.V., Shumakher G.I., Vorob'eva E.N. i dr. Kliniko-laboratornoe issledovanie effektivnosti i bezopasnosti primeneniia preparata Divaza v terapii patsientov s khronicheskoi ishemiei golovnogo mozga. Zhurn. nevrologii i psikhiatrii im. S.S.Korsakova. 2017; 2. [in Russian]

________________________________________________

1. Dahlof B. Cardiovascular disease risk factors: epidemiology and risk assessment. Am J Cardiol 2010; 105 (Suppl. 1): 3A–9A.
2. Lloyd-Jones DM, Hong Y, Labarthe D et al. Defining and setting national goals for cardiovascular health promotion and disease reduction. Circulation 2010; 121 (4): 586–613.
3. Waldman SA, Terzic A. Cardiovascular health: the global challenge. Clin Pharmacol Ther 2011; 90 (4): 483–5.
4. Lepin JP, Briley M. The increasing burden of depression. Neuropsychiatr Dis Treat 2011; 7 (Suppl. 1): 3–7.
5. Brodtmann A. Vascular risk, depression, and stroke: post hoc ergopropter hoc … or not. Neurology 2014; 83: 1688–9. DOI: 10.1212/WNL.0000000000000968
6. Kubzansky LD, Winning A, Kawachi I. Affective states and health. In: Berkman LF, Kawachi I, Glymour MM, eds. Social Epidemiology. New York: Oxford University Press, 2014; p. 320–64.
7. Gilsanz P, Kubzansky LD, Tchetgen Tchetgen EJ et al. Changes in Depressive Symptoms and Subsequent Risk of Stroke in the Cardiovascular Health Study. Stroke 2017; 48–50. DOI: 10.1161/STROKEAHA.116.013554
8. Pan A, Sun Q, Okereke OI et al. Depression and risk of stroke morbidity and mortality: a meta-analysis and systematic review. JAMA 2011; 306: 1241–9. DOI: 10.1001/jama.2011.1282
9. Dong JY, Zhang YH, Tong J, Qin LQ. Depression and risk of stroke: a meta-analysis of prospective studies. Stroke 2012; 43: 32–7. DOI: 10.1161/STROKEAHA.111.630871
10.  Wulsin L, Singal B. Do depressive symptoms increase the risk for the onset of coronary disease? A systematic quantitative review. Psychosom Med 2003; 65: 201–10.
11. Robins JM, Hernán MA, Brumback B. Marginal structural models and causal inference in epidemiology. Epidemiology 2000; 11: 550–60.
12. Gilsanz P, Walter S, Tchetgen Tchetgen EJ et al. Changes in depressive symptoms and incidence of first stroke among middle-aged and older US adults. J Am Heart Assoc 2015; 4: 19–23.
13. Dantzer R, O’Connor JC, Freund GG et al. From inflammation to sickness and depression: when the immune system subjugates the brain. Nat Rev Neurosci 2008; 9 (1): 46–56.
14. Dinan TG. Inflammatory markers in depression. Curr Opin Psychiatry 2008; 22: 32–6.
15. Haroon E, Raison CL, Miller AH. Psychoneuroimmunology Meets neuropsychopharmacology: translational implications of the impact of inflammation on behavior. Neuropsychopharmacol Rev 2012; 37: 137–62.
16. Leonard BE. The concept of depression as a dysfunction of the immune system. Curr Immunol Rev 2010; 6 (3): 205–12.
17. Irwin MR, Cole JC. Depression and psychoneuroimmunology. Human Psychoneuroimmunology [Internet]. Oxford University Press, 2005; p. 243–64.
18. Prather AA, Vogelzangs N, Penninx BWJH. Sleep duration, insomnia, and markers of systemic inflammation: Results from the Netherlands Study of Depression and Anxiety (NESDA). J Psychiatr Res 2015; 60: 95–102.
19. Motivala SJ, Sarfatti A, Olmos L, Irwin MR. Inflammatory Markers and Sleep Disturbance in Major Depression. Psychosomatic Medicine. Ovid Technologies (Wolters Kluwer Health) 2005; 67 (2): 187–94. DOI: 10.1097/01.psy.0000149259.72488.09
20. Cho HJ, Seeman TE, Kiefe CI et al. Sleep disturbance and longitudinal risk of inflammation: Moderating influences of social integration and social isolation in the Coronary Artery Risk Development in Young Adults (CARDIA) study. Brain Behav Immun 2015; 1–8. DOI: 10.1016/j.bbi.2015.02.023
21. Michetti F, Massaro A, Murazio M. The nervous system-specific S-100 antigen in cerebrospinal fluid of multiple sclerosis patients. Neuroscience Letters 1979; 11 (2): 171–5.
22. Pizzi C, Costa GM, Santarella L et al. Depression symptoms and the progression of carotid intima-media thickness: a 5-year follow-up study. Atherosclerosis 2014; 233: 530–6. DOI: 10.1016/j.atherosclerosis.2014.01.012
23. Herrmann LL, Le Masurier M, Ebmeier KP. White matter hyperintensities in late life depression: a systematic review. J Neurol Neurosurg Psychiatry 2008; 79: 619–24. DOI: 10.1136/jnnp.2007.124651
24. Aydin Sunbul E, Sunbul M, Gulec H. The impact of major depression on heart rate variability and endothelial dysfunction in patients with stable coronary artery disease. Gen Hosp Psychiatry 2017; 44: 4–9. DOI: 10.1016/j.genhosppsych
25. Tilton RG, Chang KC, LeJeune WS et al. Role for nitric oxide in the hyperpermeability and hemodynamic changes induced by intravenous VEGF. Investig Ophthalmol Vis Sci 1999; 40: 689–96.
26. Taddei S, Virdis A, Mattei P et al. Endothelium-dependent forearm vasodilation is reduced in normotensive subjects with familial history of hypertension. J Cardiovasc Pharmacol 1992; 20 (Suppl. 12): S193–S195.
27. Landmesser U, Drexler H. Endothelial function and hypertension. Curr Opin Cardiol 2007; 22 (4): 316–20.
28. Bonetti PO, Lerman LO, Lerman A. Endothelial dysfunction: a marker of atherosclerotic risk. Arterioscler Thromb Vasc Biol 2003; 23 (2): 168–75.
29. Kim JS. Cytokines and adhesion molecules in stroke and related diseases. J Neurol Sci 1996; 137: 69–78.
30. Connor TJ, Leonard BE. Depression, stress and immunological activation: the role of cytokines in depressive disorders. Life Sci 1998; 62: 583–606.
31. Thomas AJ, Ferrier IN, Kalaria RN et al. Elevation in late-life depression of intercellular adhesion molecule-1 expression in the dorsolateral prefrontal cortex. Am J Psychiatry 2000; 157: 1682–4.
32. Thomas AJ, Ferrier IN, Kalaria RN et al. Cell adhesion molecule expression in the dorsolateral prefrontal cortex and anterior cingulate cortex in major depression in the elderly. Br J Psychiatry 2002;181: 129–34.
33. Nebieridze D.V., Rogov V.A., Oganov R.G. Agonisty imidazolinovykh retseptorov: novoe pokolenie preparatov tsentral'nogo deistviia s novymi vozmozhnostiami kontrolia arterial'noi gipertonii. Ros. kardiol. zhurn. 2001; 6: 68–73. [in Russian]
34. Ota H, Eto M, Kano MR et al. Induction of endothelial nitric oxide synthase, sirt1, and catalase by statins inhibits endothelial senescence through the akt pathway. Arterioscler Thromb Vasc Biol 2010; 30: 2205–11.
35. Nemeroff CB, Musselman DL. Are platelets the link between depression and ischemic heart disease? Am Heart J 2000; 140 (Suppl. 4): 57–62.
36. Piletz JE, Halaris A, Iqbal O et al. Pro-inflammatory biomarkers in depression: treatment with venlafaxine. World J Biol Psychiatry 2009; 10: 313–23.
37. Piletz JE, Zhu H, Madakasira S et al. Elevated P-selectin on platelets in depression: response to bupropion. J Psychiatry Res 2000; 34: 397–404.
38. Charney DS, Menkes DB, Heninger GR. Receptor sensitivity and the mechanism of action of antidepressant treatment. Implications for the etiology and therapy of depression. Arch Gen Psychiatry 1981; 38: 1160–80.
39. Cook EH, Fletcher KE, Wainwright M et al. Primary structure of the human platelet serotonin 5-HT2A receptor: identify with frontal cortex serotonin 5-HT2A receptor. J Neurochem 1994; 63: 465–9.
40. Marcusson JO, Ross SB. Binding of some antidepressants to the 5-hydroxytryptamine transporter in brain and platelets. Psychopharmacology 1990; 102: 145.
41. De Clerck F. Effects of serotonin on platelets and blood vessels. J Cardiovasc Pharmacol 1991; 17 (Suppl. 5): S1–S5.
42. Nemeroff C, Musselman D. Are platelets the link between depression and ischemic heart disease? Am Heart J 2000; 140: 57–62.
43. Pollock BGM, Laghrissi-Thode FM, Wagner WRP. Evaluation of platelet activation in depressed patients with ischemic heart disease after paroxetine or nortriptyline treatment. J Clin Psychopharmacol 2000; 20: 137–40.
44. Nakashima MN, Ajiki K, Nakashima K, Takahashi M. Possible role of nitric oxide in anxiety following transient cerebral ischemia in mice. J Pharmacol Sci 2003; 91: 47–52.
45. Bonetti PO, Lerman LO, Lerman A. Endothelial dysfunction: a marker of atherosclerotic risk. Arterioscler Thromb Vasc Biol 2003; 23: 168–75.
46. Cleland SJ, Sattar N, Petrie JR et al. Endothelial dysfunction as a possible link between C-reactive protein levels and cardiovascular disease. Clin Sci 2000; 98: 531–5.
47. Markovitz JH, Shuster JL, Chitwood WS et al. Platelet activation in depression and effects of sertraline treatment: An open-label study. Am J Psychiatry 2000;157: 1006–8.
48. Ziegelstein RC, Parakh K, Sakhuja A, Bhat U. Depression and coronary artery disease: is there a platelet link? Mayo Clin Proc 2007; 82: 1366–8.
49. Tiemeier H. Vitamin B12, folate and homocysteine in depression. The Rotterdam Study. Am J Psychiatry 2002; 159: 2099–101.
50. Zhou L, Zhu DY. Neuronal nitric oxide synhase: structure, subcellular localization, regulation, and clinical implications. Nitric Oxide 2009; 20: 223–30.
51. Joca SR, Guimaraes FS. Inhibition of neuronal nitric oxide synthase in the rat hippocampus induces antidepressant-like effects. Psychopharmacology 2006; 185: 298–305.
52. Herken H, Uz E, Ozyurt H et al. Red blood cell nitric oxide levels in patient with schizophrenia. Schizophr Res 2001; 52: 289–90.
53. Miguel TT, Nunes-de-Souza RL. Anxiogenic like effects induced by NMDA receptor activation are prevented by inhibition or neuronal nitric oxide synthase in the periaqueductal gray in mice. Brain Res 2008; 13: 39–46.
54. Workman JL, Trainor BC, Finy MS et al. Inhibition of neuronal nitric oxide reduces anxiety-like responses to pair housing. Behav Brain Res 2008; 187: 109–15.
55. Iakovlev V.M., Semenkin A.A., Iudin S.M. i dr. Vliianie terapii enalaprila maleatom na funktsiiu sosudistogo endoteliia i trombotsitarno-endotelial'nye vzaimosviazi u bol'nykh gipertonicheskoi bolezn'iu. Terapevt. arkh. 2000; 1: 12–5. [in Russian]
56. Sitnikova M.Iu., Ivanov S.G., Khmel'nitskaia K.A. Farmakologicheskaia zashchita endoteliia v ramkakh standartnoi terapii khronicheskoi serdechnoi nedostatochnosti. Biul. NII kardiologii im. V.A.Almazova. 2004; 2 (1): 101–8. [in Russian]
57. Luscher TF, Noll G. The endothelium as a regulator of vascular tone and growth. The endothelium in cardiovascular disease: pathophysiology, clinical presentation, and pharmacotherapy. Berlin, 1995; p. 1–24. DOI: 10.1007/978-3-642-79803-0_1
58. Artiushkova E.B. Farmakologicheskaia korrektsiia endotelial'noi disfunktsii na ADMA-podobnoi modeli defitsita oksida azota preparatami s razlichnymi mekhanizmami deistviia kak dopolnenie k sushchestvuiushchim metodam profilaktiki i lecheniia serdechnososudistogo kontinuuma: informatsionnoe pis'mo. Kursk, 2009. [in Russian]
59. Trukhan D.I. Korrektsiia narushenii lipidnogo obmena u patsientov s metabolicheskim sindromom: fokus na rozuvastatin. Handbook for Practitioners Doctors. 2015; 11–12: 4–8. [in Russian]
60. Goncharova N.S., Moiseeva O.M. Prostanoidy pri legochnoi venoznoi gipertenzii: zachem, komu, kogda i kak? RMZh. 2015; 5: 284. [in Russian]
61. Shilov A.M. Atsetilsalitsilovaia kislota – antiagregant dlia profilaktiki i lecheniia serdechno-sosudistykh zabolevanii. Trudnyi patsient. 2013; 4: 3–8. [in Russian]
62. Petrova M.M., Salmina A.B., Inzhutova A.I., Bakhmet'eva O.S. Ingibitory APF – ratsional'naia farmakoterapiia endotelial'noi disfunktsii. Ratsional'naia farmakoterapiia v kardiologii. 2008; 2: 30–4. [in Russian]
63. Britov A.N. Endotelial'naia disfunktsiia i rol' nitratov i beta-adrenoblokatorov v ee korrektsii pri ishemicheskoi bolezni serdtsa. Ratsional'naia farmakoterapiia v kardiologii. 2016; 2: 43–7. [in Russian]
64. Belous A.S., Pokrovskaia T.G., Pokrovskii M.V. i dr. Izuchenie endotelioprotektivnykh effektov impazy v komplekse s lozartanom pri eksperimental'nom modelirovanii L-NAME indutsirovannogo defitsita oksida azota. V kn.: XV Rossiiskii natsional'nyi kongress “Chelovek i lekarstvo”. M., 2008; s. 589. [in Russian]
65. Belous A.S., Pokrovskii M.V., Pokrovskaia T.G. i dr. Endotelioprotektivnye effekty preparata impaza na 30-dnevnoi modeli L-NAME indutsirovannogo defitsita oksida azota. V kn.: XVII Rossiiskii natsional'nyi kongress “Chelovek i lekarstvo”. M., 2010; s. 579. [in Russian]
66. Pankova T.M., Starostina M.V., Shtark M.B., Epshtein O.I. Neiroprotektornoe deistvie sverkhmalykh doz antitel k belku S100 v kul'ture neiroblastomy pri deprivatsii kisloroda i gliukozy. Biul. eksperimental'noi biologii i meditsiny. 2007; 144 (9): 260–3. [in Russian]
67. Arustamova A.A. Protivoishemicheskoe i endotelioprotektivnoe deistvie potentsirovannykh antitel k endotelial'nomu faktoru rosta sosudov. Avtoref. dis. ... kand. biol. nauk. Belgorod, 2011. [in Russian]
68. Belous A.S. Otsenka korrektsii morfologicheskikh izmenenii pri modelirovanii endotelial'noi disfunktsii sverkhmalymi dozami antitel k ENOS na 28-dnevnoi modeli L-NAME indutsirovannogo defitsita oksida azota. Nauch. vedomosti. 2014; 11 (182. Vyp. 26/1): 127–30. [in Russian]
69. Khakimova G.R., Voronina T.A., Dugina Iu.L. i dr. Spektr farmakologicheskikh effektov antitel k belku S-100 v reliz-aktivnoi forme i mekhanizmy ikh realizatsii. Zhurn. nevrologii i psikhiatrii im. S.S.Korsakova. 2016; 4: 100–13. [in Russian]
70. Chukanova E.I., Bogolepova A.N., Chukanova A.S. Opyt primeneniia preparata divaza v terapii tserebrovaskuliarnoi nedostatochnosti. Zhurn. nevrologii i psikhiatrii im. S.S.Korsakova. 2015; 6: 110–4. [in Russian]
71. Fateeva V.V., Kolokolov O.V., Zakharova N.B. i dr. Khronicheskaia ishemiia golovnogo mozga. Lechashchii vrach. 2016; 5: 1–6. [in Russian]
72. Fateeva V.V., Shumakher G.I., Vorob'eva E.N. i dr. Kliniko-laboratornoe issledovanie effektivnosti i bezopasnosti primeneniia preparata Divaza v terapii patsientov s khronicheskoi ishemiei golovnogo mozga. Zhurn. nevrologii i psikhiatrii im. S.S.Korsakova. 2017; 2. [in Russian]

В.В.Фатеева*1, О.В.Воробьева1, А.Б.Глазунов2

1 ФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М.Сеченова» Минздрава России. 119991, Москва, ул. Трубецкая, д. 8, стр. 2;
2 ФГБОУ ВО «Российский национальный исследовательский медицинский университет им. Н.И.Пирогова» Минздрава России. 117997, Москва, ул. Островитянова, д. 1
*v.v.fateeva@mail.ru

________________________________________________

V.V.Fateevа*1, O.V.Vorobieva1, А.В.Glazunov2

1 I.M.Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation. 119991, Russian Federation, Moscow, ul. Trubetskaia, d. 8, str. 1;
2 N.I.Pirogov Russian National Research Medical University of the Ministry of Health of the Russian Federation. 117997, Russian Federation, Moscow, ul. Ostrovitianova, d. 1
*v.v.fateeva@mail.ru